Abstract
The article presents a study of plasma coagulation and level of fibrinolytic activity in patients with hypertension and type 2 diabetes when the nitric oxide donor L-arginine is added to the basic treatment. We have conducted an open prospective study including 109 patients. It was found significantly more substantial increasing of antithrombin III level (р<0,05), reliable decline of fibrinogen level (р<0,05), and also an increase of fibrinolytic activity (р<0,05) in the group which received L-arginine in addition to the basic treatment. It was proved that L-arginine which manifests its metabolic properties by changing the endothelial markers activity, could be recommended as an additional method of correction of plasma hemostasis and fibrinolytic activity in patients with hypertension and type 2 diabetes.
Highlights
The article presents a study of plasma coagulation and level of fibrinolytic activity in patients with hypertension and type 2 diabetes when the nitric oxide donor L-arginine is added to the basic treatment
It was proved that L-arginine which manifests its metabolic properties by changing the endothelial markers activity
Ключевые слова: гипертоническая болезнь, сахарный диабет типа 2, L-аргинин, фибринолитическая активность, плазминоген, антитромбин III, протеин С
Summary
Вищий державний навчальний заклад України «Буковинський державний медичний університет», м. Подальшою задачею дослідження було встановлення вірогідності змін фібринолітичного потенціалу плазми крові у хворих на АГ та ЦД типу 2 після додавання до комплексної терапії метаболічного засобу порівняно з базисним лікуванням. При зіставленні змін ПАП у динаміці лікування в обстежених хворих виявлено підвищення його активності з (16,12±0,28) до (16,4±0,34) хв у групі 1 (p
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
